Artrya (ASX:AYA)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Artrya.
RELATED STOCKHEAD STORIES
Health Check: Mayne Defenders fight ‘inadequate’ takeover offer
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Health Check: You’re rehired! The Trump administration’s FDA staffing ‘fiasco’ puts sector in choppy, unchartered waters
Health Check: More, please! When record results are not good enough for expectant investors
Health Check: Despite a ‘biggest ever’ December half, Pro Medicus says it’s just revving up in the US
Biocurious: Hut Hut Hut! The growing list of ASX biotechs waiting for the FDA to call the start of play
ASX January Health Winners: Artrya and EBR among the leaders in strong month
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
Health Check: It’s all in the vibe as Invion and Wellness Life shrink to share greatness
Health Check: Probiotics supplier has gut feeling about surging growth
ASX medtechs at heart of growing cardiac care market
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
ASX Health Stocks: NSB jumps 30pc after disclosing upcoming meeting with US FDA
